Cargando…
Research progress of nanovaccine in anti-tumor immunotherapy
Tumor vaccines aim to activate dormant or unresponsive tumor-specific T lymphocytes by using tumor-specific or tumor-associated antigens, thus enhancing the body’s natural defense against cancer. However, the effectiveness of tumor vaccines is limited by the presence of tumor heterogeneity, low immu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484753/ https://www.ncbi.nlm.nih.gov/pubmed/37692854 http://dx.doi.org/10.3389/fonc.2023.1211262 |
_version_ | 1785102650863255552 |
---|---|
author | Yao, Min Liu, Xiyu Qian, Zhangbo Fan, Dianfa Sun, Xinjun Zhong, Liping Wu, Pan |
author_facet | Yao, Min Liu, Xiyu Qian, Zhangbo Fan, Dianfa Sun, Xinjun Zhong, Liping Wu, Pan |
author_sort | Yao, Min |
collection | PubMed |
description | Tumor vaccines aim to activate dormant or unresponsive tumor-specific T lymphocytes by using tumor-specific or tumor-associated antigens, thus enhancing the body’s natural defense against cancer. However, the effectiveness of tumor vaccines is limited by the presence of tumor heterogeneity, low immunogenicity, and immune evasion mechanisms. Fortunately, multifunctional nanoparticles offer a unique chance to address these issues. With the advantages of their small size, high stability, efficient drug delivery, and controlled surface chemistry, nanomaterials can precisely target tumor sites, improve the delivery of tumor antigens and immune adjuvants, reshape the immunosuppressive tumor microenvironment, and enhance the body’s anti-tumor immune response, resulting in improved efficacy and reduced side effects. Nanovaccine, a type of vaccine that uses nanotechnology to deliver antigens and adjuvants to immune cells, has emerged as a promising strategy for cancer immunotherapy due to its ability to stimulate immune responses and induce tumor-specific immunity. In this review, we discussed the compositions and types of nanovaccine, and the mechanisms behind their anti-tumor effects based on the latest research. We hope that this will provide a more scientific basis for designing tumor vaccines and enhancing the effectiveness of tumor immunotherapy. |
format | Online Article Text |
id | pubmed-10484753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104847532023-09-09 Research progress of nanovaccine in anti-tumor immunotherapy Yao, Min Liu, Xiyu Qian, Zhangbo Fan, Dianfa Sun, Xinjun Zhong, Liping Wu, Pan Front Oncol Oncology Tumor vaccines aim to activate dormant or unresponsive tumor-specific T lymphocytes by using tumor-specific or tumor-associated antigens, thus enhancing the body’s natural defense against cancer. However, the effectiveness of tumor vaccines is limited by the presence of tumor heterogeneity, low immunogenicity, and immune evasion mechanisms. Fortunately, multifunctional nanoparticles offer a unique chance to address these issues. With the advantages of their small size, high stability, efficient drug delivery, and controlled surface chemistry, nanomaterials can precisely target tumor sites, improve the delivery of tumor antigens and immune adjuvants, reshape the immunosuppressive tumor microenvironment, and enhance the body’s anti-tumor immune response, resulting in improved efficacy and reduced side effects. Nanovaccine, a type of vaccine that uses nanotechnology to deliver antigens and adjuvants to immune cells, has emerged as a promising strategy for cancer immunotherapy due to its ability to stimulate immune responses and induce tumor-specific immunity. In this review, we discussed the compositions and types of nanovaccine, and the mechanisms behind their anti-tumor effects based on the latest research. We hope that this will provide a more scientific basis for designing tumor vaccines and enhancing the effectiveness of tumor immunotherapy. Frontiers Media S.A. 2023-08-24 /pmc/articles/PMC10484753/ /pubmed/37692854 http://dx.doi.org/10.3389/fonc.2023.1211262 Text en Copyright © 2023 Yao, Liu, Qian, Fan, Sun, Zhong and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yao, Min Liu, Xiyu Qian, Zhangbo Fan, Dianfa Sun, Xinjun Zhong, Liping Wu, Pan Research progress of nanovaccine in anti-tumor immunotherapy |
title | Research progress of nanovaccine in anti-tumor immunotherapy |
title_full | Research progress of nanovaccine in anti-tumor immunotherapy |
title_fullStr | Research progress of nanovaccine in anti-tumor immunotherapy |
title_full_unstemmed | Research progress of nanovaccine in anti-tumor immunotherapy |
title_short | Research progress of nanovaccine in anti-tumor immunotherapy |
title_sort | research progress of nanovaccine in anti-tumor immunotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484753/ https://www.ncbi.nlm.nih.gov/pubmed/37692854 http://dx.doi.org/10.3389/fonc.2023.1211262 |
work_keys_str_mv | AT yaomin researchprogressofnanovaccineinantitumorimmunotherapy AT liuxiyu researchprogressofnanovaccineinantitumorimmunotherapy AT qianzhangbo researchprogressofnanovaccineinantitumorimmunotherapy AT fandianfa researchprogressofnanovaccineinantitumorimmunotherapy AT sunxinjun researchprogressofnanovaccineinantitumorimmunotherapy AT zhongliping researchprogressofnanovaccineinantitumorimmunotherapy AT wupan researchprogressofnanovaccineinantitumorimmunotherapy |